A 38-year-old African-American woman with an unusually rapid progression of "Primary biliary cirrhosis": A missed opportunity!

Seminars in Liver Disease

Volumn 22, Issue 4, 2002, Pages 395-405

  Van Leeuwen, Dirk J ^a,b   Sood, Gagan ^b   Ferrante, Dino ^b   Lazenby, Audrey J ^c   Sellers, Marty J ^d  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d Kentucky   (United States)

Author keywords

Acute hepatitis; Antimitochondrial antibody; Autoimmune hepatitis; Immunosuppression; Liver biopsy; Liver regeneration; Liver transplantation; Overlap syndrome; Primary biliary cirrhosis; Subfulminant liver failure; Variant syndrome

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MITOCHONDRION ANTIBODY; SMOOTH MUSCLE ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; ASCITES; AUTOIMMUNE HEPATITIS; BILE DUCT OBSTRUCTION; BILIARY CIRRHOSIS; BRAIN DISEASE; CASE REPORT; CHOLECYSTECTOMY; CHOLELITHIASIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; JAUNDICE; LABORATORY TEST; LIVER BIOPSY; LIVER FAILURE; LIVER NECROSIS; LIVER NODULE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT PLANNING;

ADULT; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; TIME FACTORS;

EID: 0036852079     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35710     Document Type: Article

References (51)

1. Holt C, Csete M, Martin P. Hepatotoxicity of anaesthetics and other central nervous system drugs. Gastroenterol Clin North Am 1995;24:853-874.
2. Gitlin N, Serio KM. Ischemic hepatitis: Widening horizons. Am J Gastroenterol 1992;87:831-836.
3. Isogai M, Hachisuka K, Yamaguchi A. Etiology and pathogenesis of marked elevation of serum transaminases in patients with acute gallstone disease. HPB Surg 1991;4:95-107.
4. Harrison HB, Middleton HM II, Crosby JH, Dasher MN Jr. Fulminant hepatic failure: An unusual presentation of metastatic liver disease. Gastroenterology 1981;80:820-25.
5. Colby TV, LaBrecque DR. Lymphoreticular malignancy presenting as fulminant hepatic disease. Gastroenterology 1982; 80:820-825.
6. Bass NM, Burroughs AK, Scheuer PJ. Chronic intrahepatic cholestasis due to sarcoidosis. Gut 1982;23:417-423.
7. Murphy JR, Sjogren MH, Kikendall JW, Peura DA, Goodman Z. Small bile duct abnormalities in sarcoidosis. J Clin Gastroenterol 1990;12:555-561.
8. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
9. Kaplan M. Primary biliary cirrhosis. N Engl J Med 1996; 335:1570-1580.
10. Wiesner RH. Liver transplantation for PBC and primary sclerosing cholangitis: Predicting outcome with natural history models. Mayo Clin Proc 1998;73:575-588.
11. Christensen E, Gunson B, Neuberger J. Optimal timing of liver transplantation for patients with primary biliary cirrhosis: Use of prognostic modeling. J Hepatol 1999;30:285-292.
12. Loose AW, Meyer um Buschenfelde H, Franz B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-1084.
13. Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology 1998;28:296-301.
14. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-598.
15. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with acute presentation. J Hepatol 1994;21:866-871.
16. Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr Gastroenterol Nutr 1990;116:97-106.
17. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000;32(Suppl 1):181-197.
18. Autoimmune hepatitis: The investigational and clinical challenges. AASLD Clinical Research Single Topic Conference. Abstracts of presentations. September 16-18, 1999; Atlanta, Georgia.
19. McFarlane IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 1998;42:599-602.
20. Gregorio G, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: A 20-year experience. Hepatology 1997;25: 541-547.
21. Johnson PJ, McFarlane IG. Meeting report. International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
22. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Study Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;3:929-938.
23. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: An unusual form of presentation. J Hepatol 1997;27:578-582.
24. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: Definitions and causes. Semin Liver Dis 1986;6:97-106.
25. Waldenstrom J. Leber, blutproteine und nahrungseiweiss. Dtsch Z Verdau Stoffwechselkr 1950;2:113-119.
26. Mackay IR, Taft LT, Cowling DC. Lupoid hepatitis. Lancet 1956;ii:123-126.
27. MacKay IR. Treatment of chronic active hepatitis and other liver disease with corticosteroid agents. Med J Aust 1987;146: 370-374.
28. Maddrey WC. Drug-induced chronic active hepatitis. In: Krawitt EL, Wiesner RH, eds. Autoimmune Liver Diseases. New York: Raven Press; 1991:219-232.
29. Shukla M, van Leeuwen DJ. Drug-induced vs. autoimmune hepatitis? Don't delay steroids. AGC National Fellow's Forum, April 1996; Scottsdale Arizona/American College of Gastroenterology, October 1996, Abst.
30. Lam KC, Yuen P, Colbourne MJ, Chang J, So S. Deleterious effect of prednisolone in HBsA positive chronic active hepatitis. N Engl J Med 1981;304:380.
31. Czaja A, Manns MP, McFarlane IG, Hoofnagle JH. Autoimmune hepatitis: The investigational and clinical challenges. Hepatology 2000;31:1194-1200.
32. Zauli D, Cassani F, Bianchi FB. Cytoskeletal antigens. In: McFarlane IG, Williams R, eds. Molecular Basis of Autoimmune Hepatitis. Austin, TX: RG Landes; 1996:45-58.
33. Walker JG, Doniach D, Roitt IM. Serological tests in the diagnosis of primary biliary cirrhosis. Lancet 1965;1:827-831.
34. Doniach D, Roitt IM, Walker JG, Sherlock S. Tissue antibodies in primary biliary cirrhosis, active chronic lupoid hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol 1966;3:237-262.
35. Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis: Chronic nonsuppurative destructive cholangitis. Am J Pathol 1965;46:387-407.
36. Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med 1967; 60:1257-1260.
37. Berg PA, Klein R. Autoantibody patterns in primary biliary cirrhosis. In: Krawitt EL, Wiesner RH, eds. Autoimmune Liver Diseases. New York: Raven Press; 1991:123-142.
38. Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986;31:705-711.
39. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: Part of spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18:10-15.
40. Goodman Z, McNally PR, Davis DR, Ishak KO. Autoimmune cholangitis: A variant of primary biliary cirrhosis. Dig Dis Sci 1995;40:1232-1242.
41. Heathcote JE. Autoimmune cholangitis. Clin Liver Dis 1998; 2:303-311.
42. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: A meta analysis. Lancet 1999;354:1053-1060.
43. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. Gastroenterology 1999;117:918-925.
44. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;31:318-323.
45. Kurktschiev D, Subat S, Adler D, Schentke KU. Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. J Hepatol 1993;18:373-377.
46. O'Grady JG, Alexander GJM, Hallyar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:437-445.
47. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984;37:363-365.
48. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic hepatitis. Hepatology 1992;15:215-221.
49. Milkiewicz P, Hubscher SG, Skiba G, et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68:253-256.
50. Trouillot TE, Shrestha R, Kam I, et al. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl Surg 1999;5:375-380.
51. Jones DE, James OF, Portmann B, et al. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999;30:53-57.